{"database": "openregs", "table": "dockets", "rows": [["FDA-2026-P-5194", "FDA", "Requests that the FDA declare that the drug product Naltrexone Hydrochloride Oral Suspension, 5 mg/mL, is suitable for consideration\nin an Abbreviated New Drug Application.", "Nonrulemaking", "2026-05-11T17:17:25Z", "0b000064b92cf43e"]], "columns": ["id", "agency_id", "title", "docket_type", "last_modified", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2026-P-5194"], "units": {}, "query_ms": 0.39934110827744007, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}